
OBJECTIVE Describe pharmacological management approaches to pediatric paroxysmal sympathetic hyperactivity (PSH) among North American pediatric attending physicians. PARTICIPANTS AND METHODS Cross-sectional web-based survey of pediatric attending physicians conducted from March to August 2023. The questionnaire examined PSH medication utilization and preferences, subspecialty responsibilities for managing PSH, and the influence of patient age on medication selection. Descriptive statistics summarize PSH medication utilization and rank-order preferences. Chi-square analyses examined relationships between physician specialty and medication selection. RESULTS Among 295 respondents (33% palliative care, 23% neurology, 18% complex care, 17% physiatry), considerable heterogeneity in PSH pharmacotherapy approaches was observed. The most used abortive PSH medications were gamma-aminobutyric acid A (GABA-A) agonists (86%), alpha-2 agonists (79%), and opioids (49%). Leading preventive PSH medications included alpha-2 agonists (90%), gabapentinoids (89%), and beta-blockers (66%). Top-ranked medications for abortive management were alpha-2 agonists, GABA-A agonists, and non-opioid analgesics; and gabapentinoids, alpha-2 agonists, and beta-blockers for preventive management. While physiatrists and neurologists were most frequently identified as primary managers of PSH at participants’ home institutions, several other specialties (including multidisciplinary models) were reported as well. We observed significant differences in utilization of alpha-2 agonists, opioids, dopamine agonists, and beta-blockers across subspecialties (all P < .05). Patient age influenced medication selection among 41% of our sample. CONCLUSIONS Pharmacologic management of pediatric PSH currently lacks clinical consensus and varies significantly based on physician subspecialty. Our findings underscore the need for focused research efforts to identify optimal treatment strategies and develop standardized and evidence-based management guidelines.
BACKGROUND AND OBJECTIVES: Traditional pediatric asthma education is often fragmented and time limited. Social media may provide a more sustained platform for education. We hypothesized that social media-based education (SME) about asthma would reduce health care use the year after asthma hospitalization. METHODS: In a 2-center Bayesian randomized trial, caregivers of patients aged 3 to 17 years hospitalized for asthma were randomly assigned to social media plus usual care or usual care alone, stratified by age (3-11 vs 12-17 years) and center. The SME group received at least weekly educational post via Facebook and Instagram. The primary outcome was total number of treatment days in a medical setting within 1 year. Secondary outcomes included treatment days across different settings, time to emergency department (ED) revisit or hospital readmission, missed school days, and patient satisfaction. Analyses were conducted using Bayesian generalized linear models with a neutral prior. RESULTS: Two hundred participants were enrolled. Compared with usual care, SME had a 93% probability of reduced total treatment days (relative risk [RR] 0.80; 95% credible interval [CrI], 0.59-1.07) and a 96% probability of decreased unplanned treatment days (RR 0.67; 95% CrI, 0.43-1.05). Mean time to ED revisit was 186 days in controls vs 225 days in the SME arm, with a 92% probability of reduction. Social media participants had longer time to readmission (293 vs 218 days; 81% probability of reduction) and greater satisfaction with education (73% vs 36%) than controls. CONCLUSIONS: SME was well accepted and likely reduced health care use and delayed posthospitalization ED visits and readmissions compared with usual care.
Children whose caregivers use languages other than English (LOE) experience persistent inequities in pediatric health care yet remain systematically underrepresented in research. Inpatient pediatric studies present distinct challenges to achieving language-equitable research, including complex clinical workflows and variable regulatory requirements. Prior literature highlights the importance of including participants who use LOE in pediatric research, but practical methodological guidance tailored to inpatient settings remains limited. We outline a framework to support pediatric hospitalists in designing rigorous studies that more fully include families who use LOE as participants and partners. We provide actionable strategies to promote language equity across the full research lifecycle, including study design, budgeting, recruitment, consent, data collection, analysis, reporting, and dissemination. These strategies address common inpatient challenges such as interpreter logistics, institutional review board variability, and minimizing participant burden during hospitalization. By anticipating language needs and incorporating inclusive design principles throughout the research process, hospitalists can generate more representative evidence to inform equitable care for all children and families, regardless of language.